Skip to Content

McKinsey to Pay $573 Million Over Role in Opioid Crisis

THURSDAY, Feb. 4, 2021 -- A deal has been reached for business consulting firm McKinsey & Company to pay $573 million to settle U.S. lawsuits over its role in the nation's opioid crisis, according to a person with knowledge of the agreement.

The global company faced legal action from the District of Columbia and dozens of states and territories for advising companies on how to "supercharge" sales of prescription opioids, the Associated Press reported.

Most of the money in the national settlement would be distributed to states in less than a year and be used to combat the opioid overdose epidemic. Announcements about the settlement are expected Thursday.

For the past few years, state and local governments have been filing lawsuits against companies that make and sell prescription opioids for their role in the opioid crisis, but going after a consulting firm is a new tactic, the AP reported.

As of Wednesday night, the company had not responded to calls or emails from the news service.

Associated Press Article

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Read this next

Prescription Opioid Misuse Tied to Increased Suicide Behaviors in Youth

MONDAY, March 1, 2021 -- Youth with prescription opioid misuse (POM), especially current POM, have an increased risk for suicide-related behaviors, according to a study published...

Estimated Opioid-Related Costs $14 Billion for Symptomatic Knee OA

THURSDAY, Feb. 25, 2021 -- The total lifetime opioid-related costs generated by symptomatic knee osteoarthritis (SKOA) in the United States are $14.0 billion, about half of which...

Text Message System Useful for Monitoring Postoperative Opioid Use

TUESDAY, Feb. 23, 2021 -- A text message system can monitor postoperative opioid use and shows that many prescribed opioid tablets are unused, according to a case study published...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.